Trial Profile
The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2019
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Early breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics; Therapeutic Use
- 24 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Sep 2015 New trial record